Showing results (81-90 of 689) with videos related to

Sort By:
Pageof 69
Diabetes Care|June 15, 2018
Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized TrialMichael A Nauck, Thomas Jon Jensen, Carina Rosenkilde, et al.
AJNR. American Journal of Neuroradiology|March 15, 2003
Aortic arch origin of the left external carotid artery and type II proatlantal fetal anastomosisMichael Horowitz, Surendra Bansal, Kush Dastur
Diabetes, Obesity & Metabolism|June 15, 2016
Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatmentOleg Baranov, Melanie Kahle, Carolyn F Deacon, et al.
Diabetes, Obesity & Metabolism|October 7, 2016
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetesMichael A Nauck, Melanie Kahle, Oleg Baranov, et al.
Diabetes, Obesity & Metabolism|October 8, 2016
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patientsMirna S Abd El Aziz, Melanie Kahle, Juris J Meier, et al.
Acta Diabetologica|March 14, 2020
Risk of hypoglycaemia associated with professional, recreational, and traffic-related activities in patients with type 2 diabetes: a cross-sectional study by questionnaireAnne Jitschin, Sibylle Schleser-Mohr, Almut Stierling, et al.
The British Journal of Nutrition|February 14, 2006
The hypotensive response to oral fat is comparable but slower compared with carbohydrate in healthy elderly subjectsRenuka Visvanathan, Michael Horowitz, Ian Chapman
Nutrition Reviews|June 25, 2002
Carbohydrate and satietyChristine Feinle, Deirdre O'Donovan, Michael Horowitz
The American Journal of Medicine|July 9, 2010
Confronting the type 2 diabetes epidemic: the emerging role of incretin-based therapiesVivian A Fonseca, Bernard Zinman, Michael A Nauck, et al.
Diabetes|November 5, 2013
Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucoseIrfan Vardarli, Elisabeth Arndt, Carolyn F Deacon, et al.
Pageof 69